Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences

Contributed Commentary by Petra Streng and Mandar Paralkar, SAP 

November 5, 2026 | Emerging public-cloud ERP-based GxP compliance solutions will be good for life sciences businesses beyond just sharply reducing compliance overhead. Public-cloud ERP GxP will ensure product quality and patient safety, speed up innovation, stoke growth, appeal to investors, improve responsiveness to market moves, smooth M&A efforts, and enable AI-driven efficiencies. 
 
Those in the pharmaceutical and medical device industries are no strangers to GxP. Rooted in U.S. FDA, EU GMP, and other safety, quality, and integration guidelines, the “Good Practices” of GxP aim to ensure patient safety, product quality, and data integrity. The “x” is a placeholder for the realms Good Practice rules apply to: manufacturing, laboratory, clinical, and distribution. Wherever applied, GxP serves as a strict, demanding compliance taskmaster. 

Gxp Bottlenecks Slow Down Life Sciences Companies That Need Speed 

GxP ensures product quality and patient safety. That has been good for patients, no question. But it has made life harder for life sciences firms below the tier of giants with budgets for private-cloud GxP solutions. Life sciences firms have had no choice but to go with a patchwork of on-prem workflow-specific GxP tools with (typically) cloud-based ERP and other systems.  

That led to GxP compliance as a bottleneck that slowed innovation cycles and raised system development, enhancement, and maintenance costs. Public-cloud ERP GxP changes that, delivering business benefits that translate into greater attractiveness in the eyes of business partners as well as investors.   

The direct costs of today’s GxP-compliance bottleneck are well familiar. Computerized system validation, or CSV, can take months of added IT and compliance effort, and the direct costs of GxP-related data validation typically account for about 25% of an IT effort. 

But that understates the true costs. In GxP-regulated life sciences companies, those IT bottlenecks throw sand in the gears of the company’s innovation engine. They also hamper the responsiveness required to set the pace of, or keep pace with, fast-changing business environments.  

How Can Gxp In The Public Cloud Change That? 

First, public-cloud ERP GxP can far more easily support the ongoing transition from documentation-heavy, cumbersome CSV to CSA, or computer software assurance. That’s the FDA’s new, risk-based approach to assuring life-sciences-related software compliance. 

CSV involves thorough, universal scrutiny and documentation of a firm’s software. CSA, in contrast, considers a particular software’s impact on product quality, patient safety, or other factors and allows GxP to adjust based on those factors. Crucially, CSA is more about consistent, ongoing monitoring than one-off, regulator-focused deep dives.  

Second, public-cloud ERP GxP is integrated with cloud-based ERP and operational software. That builds compliance throughout a life sciences company’s core operations, from R&D and product development on through to supply chain, procurement, manufacturing, and logistics. Such integration delivers the compliance-related business advantages and auditability enjoyed by industry giants, but without the private-cloud price tag. 

Third, public cloud ERP-based GxP systems reduce manual effort and improve accuracy through automation. While keeping humans in the loop as the ultimate decision makers, these systems employ a growing suite of AI agents to drastically speed the pace of GxP-related data validation. They are already in private-cloud production at several global pharma companies.  

GxP change release assessment agents, for example, analyze product code changes and release documentation and map them to the product service catalog. More broadly speaking, GxP change release assessment agents support software validation/assurance staff in performing risk-based impact assessments and executing compliance change processes based on the results of those risk assessments. These agents alone have been shown to cut impact-assessment time in the range 40% to 60%, not to mention reducing errors along the way.  

How is that possible? Today’s manual software reviewers must plow through release notes and bug-fix descriptions that mix technical, functional, and operational changes by the dozens or even hundreds per release. GxP change release assessment agents can quickly cut through the noise, identify the key changes, and risk-stratify them. That lets staff focus on the impacts of changes on patient safety and prioritize them quickly and strategically. 

Another example of emerging AI agents for cloud-based GxP systems are AI impact generators that scan the actual code for changes; build dependency graphs across upstream as well as downstream applications; perform automated GxP assessments to evaluate operational continuity, data integrity, traceability, and product quality; and export impact analyses for regulatory audits. 

Gxp Compliance In The Public Cloud Is Rocket Fuel For Life Sciences IT Development  

Public cloud ERP-based GxP fundamentally changes how IT gets done in the life sciences business. Rather than upgrading systems once every few years and then spending months on validation, this approach enables a continuous flow of innovative software capabilities and rolling, heavily automated GxP validation along the way. 

Bigger picture, consider the business benefits these public-cloud GxP compliance systems can confer to life sciences companies. In addition to lower costs, less manual labor, and simpler system architectures, you’re taking the GxP-compliance brakes off R&D, product development, production, and distribution. That speeds your innovation cycle and makes you more agile and competitive. You’re also standardizing on cloud-based systems, and that positions you for consistent governance and smoother integration of acquisitions—or maybe your own acquisition. With public cloud ERP-based GxP, Good Practice makes things better for firms across the life sciences spectrum.  

Mandar Paralkar is SAP’s global vice president of life sciences, overseeing global business performance, strategic planning, partnerships, and industry innovation. With nearly 30 years of experience, he advises pharmaceutical, biotechnology, medical device, and healthcare companies on technology-driven solutions, supply chain optimization, and digital transformation to improve business performance and value. He can be reached at [email protected] 

Petra Streng, a product manager for life sciences product manager at SAP, has focused on helping SAP customers design, develop, and implement life sciences and healthcare solutions for more than two decades. She can be reached at [email protected].